Have another look at this conjunctivitis study, released in June 21.
www.ncbi.nlm.nih.gov/pmc/articles/PMC8201124/
What caught my eye was this. According to Jeremy Paul et all:-
“Further development of astodrimer sodium as a topical antiviral therapy for adenoviral ocular infections is indicated.“
Not “Commercialisation”, but “Further development”. After how many years?!
I am sure some employees still think Starpharma is still a government research centre, funded for ever by the general public.
Ann: US patent issued for DEP cabazitaxel nanoparticle, page-24
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |